Quote from bsdinsight on 5 May 2025, 08:05

Excited to Present My Third Financial Model for Rameda Pharmaceuticals!🎉
This comprehensive model includes:
-Spreading Financial Statement Analysis
-Ratio Analysis
-Common Size (Vertical & Horizontal) Analysis
-Break-Down Analysis
-Supporting Schedule
-Loans Schedule
-Regression Analysis
-WACC Calculation
-DCF Valuation
-Beta Calculation
-Comparable Analysis
-Altman Z-Score
-Charts and Graphs
– Valuation Summary

As part of this model, I conducted an Altman Z-Score analysis to assess Rameda Pharm.’s financial health over the past five years. The company has consistently remained in the Grey Zone, indicating moderate financial distress risk and emphasizing the importance of ongoing monitoring. However, based on my financial projections, improving margins, and a stabilizing capital structure, I anticipate a shift toward the Safe Zone, reflecting improved creditworthiness and operational resilience.

To assess intrinsic value, I employed both Free Cash Flow to the Firm (FCFF) and Free Cash Flow to Equity (FCFE) approaches.

Special thanks to my friend ahmed abdelqader for his invaluable assistance in building this model.